bvd-523 Report issue

Small molecule Experimental
AACT ChEMBL PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CC(C)Nc1cc(-c2c[nH]c(C(=O)N[C@H](CO)c3cccc(Cl)c3)c2)c(Cl)cn1
  • InChIKey: KSERXGMCDHOLSS-LJQANCHMSA-N
  • Mol. Mass: 433.34
  • ALogP: 4.67
  • ChEMBL Molecules:
    ulixertinib  
    ulixertinib  
More Chemistry

Pharmacology

Alternative names

bvd-523 | ulixertinib | vrt-752271

Organizations (12)

Research & Development (12)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (28)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (28)


 

Colorectal Neoplasms (Phase 1)

Ependymoma (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Genes (Phase 2)

Glioma (Phase 2)

Healthy Volunteers (Phase 1)

Hepatoblastoma (Phase 2)

Histiocytosis, Langerhans-Cell (Phase 2)

Leukemia, Hairy Cell (Phase 2)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Medulloblastoma (Phase 2)

Melanoma (Phase 2)

Mutation (Phase 2)

Myelodysplastic Syndromes (Phase 1/Phase 2)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 2)

Neoplasms, Germ Cell and Embryonal (Phase 2)

Neuroblastoma (Phase 2)

Neuroectodermal Tumors (Phase 2)

Osteosarcoma (Phase 2)

Pancreatic Neoplasms (Phase 1)

Proto-Oncogene Proteins B-raf (Phase 2)

Rhabdoid Tumor (Phase 2)

Rhabdomyosarcoma (Phase 2)

Sarcoma (Phase 2)

Sarcoma, Ewing (Phase 2)

Wilms Tumor (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 13
  • # of Trial Organizations: 12

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue